O bsessive-compulsive disorder (OCD) is a chronic debilitating disorder with a lifetime prevalence of 2% to 3%. 1 Currently, selective serotonin reuptake inhibitors (SSRIs) and cognitive behavior therapy are considered as the first-line treatment for OCD. 2 However, up to 50% of patients with OCD have failed to respond in SSRI trials. 3 In addition, SSRIs may have adverse effects that impair long-term patient adherence with these medications (eg, sexual dysfunction), 4 so looking for pharmacological alternatives in treatment of OCD seems necessary.
Duloxetine is classified as a serotonin and norepinephrine reuptake inhibitor (SNRI) . It has demonstrated efficacy, safety, and tolerability in patients with major depressive disorder. [5] [6] [7] The rationale for using duloxetine in patients with OCD comes from several lines of evidence: first, duloxetine is an SNRI, and studies have shown that duloxetine inhibits serotonin to a greater degree than norepinephrine. 8 According to Stahl et al, 9 duloxetine has a 10-fold selectivity for serotonin. Because serotonergic agents are known as the most effective treatments for OCD, duloxetine with its effects on serotonin can be studied for the treatment of OCD as well. Second, venlafaxine, another SNRI with a similar mechanism of function to duloxetine, has shown efficacy in treatment of OCD in several controlled clinical trials 10, 11 ; and third, there are some case reports and small open studies that have shown efficacy of duloxetine in treatment of OCD. [12] [13] [14] [15] In this study, our objective is to compare the efficacy of duloxetine to sertraline (a Food and Drug Administration-approved medication for treatment of OCD) as augmenting agents in treatment of patients with resistant OCD.
METHODS

Patients
Patients were recruited from the Hafez psychiatry clinic affiliated with Shiraz University of Medical Sciences from October 2015 to March 2016. The patients were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for OCD by a board-certified psychiatrist through Structured Clinical Interview for DSM-IV, Clinical Version. Exclusion criteria were any other axis I and II diagnosis, major medical problems (cardiovascular, pulmonary, renal, or gastrointestinal diseases), pregnancy, and substance or alcohol abuse. All the patients provided informed consent, and the study was approved by the ethics committee of Shiraz University of Medical Sciences that adheres to the Declaration of Helsinki Ethical Principles for Medical Research involving human subjects. Patients had failed an average (SD) of 2.2 (1.8) SSRI trials judged to be of adequate dose and duration before the start of our study. In their current trial before our intervention, they had failed to respond to at least 12 weeks of treat- 
Procedure
This study was designed as a double-blind, controlled clinical trial. The patients were placed in 1 of the 2 treatment groups randomly: sertraline or duloxetine. We used a standard randomization procedure generated by computer to have random sample set. The sertraline and duloxetine tablets had the same shape and color. The patients and the examiner were blind about consuming the medication because the same number of similar pills was provided. The ratings were done by the examiner who was a trained psychologist and unaware of adverse events. Treatment duration was 8 weeks. Subjects were interviewed at screening, baseline, and biweekly till the end of the study. Safety and tolerability were assessed using spontaneously reported adverse event data and rates of premature termination for adverse effects. During the trial, no other psychological or medical intervention was allowed. 
Measurements
The primary efficacy measure was Y-BOCS. 16, 17 The Y-BOCS was administered before starting the treatment and at the end of week 8. The efficacy index of Clinical Global Improvement was used at the end of the study.
Statistical Analysis
There is no standard cutoff point for Y-BOCS. One previous study considered a more than 34% decline in Y-BOCS to medication as the response rate. 18 In another study conducted on patients with resistant OCD, a more than 25% decrease in Y-BOCS was the cutoff point. 19 In this current trial that is about resistant OCD, a decline of more than 25% in total Y-BOCS score was considered as respondent.
We compared the demographic and clinical characteristics of the groups at baseline using χ 2 and Mann-Whitney U tests. The
Mann-Whitney U test was used to compare the 2 groups for significantly different effects, and the Wilcoxon signed rank test computed the differences within groups. Response rates were compared between the groups at the end point. The analysis was performed only on completers. The data are presented as mean (SD). All P values were 2-tailed, and statistical significance was set at the 5% level. Statistical assessments were performed by SPSS for Windows version 19, IBM SPSS Statistics Corporation.
RESULTS
Of seventy patients with OCD who were eligible to enter the study, 57 patients gave written consent to enter our survey. Forty-six patients (24 of 30 in the duloxetine group and 22 of 27 in the sertraline group) completed the trial. The dropouts occurred any time during the study and were due to adverse events. In the duloxetine group, the patient withdrawals were due to gastrointestinal disturbances (n = 4), headache (n = 1), and sexual problems (n = 1). In the sertraline group, 5 patients dropped out from the trial due to gastrointestinal disturbances (n = 3), headache (n = 1), and sexual disturbances (n = 1).
The mean age of the patients was 42. 2 years; 59.7% of the participants were women. Demographic and baseline clinical characteristics are shown in Table 1 . There was no significant difference between the 2 groups regarding demographic and baseline clinical characteristics.
All patients had both obsessive and compulsive symptoms. Primary obsessive symptoms according to the Y-BOCS checklists were contamination obsessions (64.7%) and obsessions with need for symmetry and exactness (24.8%). Primary compulsive symptoms were repeating rituals (39.1%) and washing-cleaning compulsions (41.3%). Both groups showed improvement during the 8-week study period (mean Y-BOCS total score at week 8 as compared with baseline: P < 0.001 & P < 0.001) without significant difference (P = 0.861) ( Table 2) .
Those receiving duloxetine plus their initial medications experienced a mean decrease of 33.0% in Y-BOCS score, and the patients taking sertraline added to their initial medication experienced a mean decrease of 34.5% in Y-BOCS. Fifteen patients in the duloxetine group and 13 patients in the sertraline group were considered responders.
DISCUSSION
Our double-blind comparative clinical trial demonstrates that duloxetine was as effective as sertraline in reducing obsessions and compulsions in patients with resistant OCD.
In a review of the literature regarding the effects of SNRIs on patients with OCD, we found several published case reports and open studies on the successful treatment of OCD with venlafaxine. [20] [21] [22] In a 1996 double-blind, placebo-controlled study, Yaryura-Tobias and Neziroglu enrolled 16 outpatients with OCD into an 8-week investigation of venlafaxine. A total of 42.9% of their patients on venlafaxine compared with 0 patients on placebo showed improvement. 8 In a double-blind Dutch study comparing venlafaxine 
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extended release with paroxetine, Denys et al demonstrated there was no difference in response rate (ie, both drugs were equally effective). 9 Furthermore, Denys et al, 23 in a double-blind switch study of serotonin reuptake inhibitors (SRI), showed that 42% of the nonresponders benefited from a crossover to the other SRI, and that paroxetine was more efficacious than venlafaxine in the treatment of nonresponders to a previous SRI trial. Duloxetine is a new SNRI that has shown efficacy for treatment of major depressive disorder in several studies. [5] [6] [7] A small body of evidence supports the efficacy of duloxetine for the treatment of OCD. 24 Previous studies include case reports [12] [13] [14] and a small open-label study. 15 The results of our double-blind, controlled clinical trial are consistent with previous SNRI studies in treatment of OCD. These studies have suggested that SNRIs can serve as useful alternatives for the treatment of OCD.
In a review of the literature, we found that augmenting serotonergic agents with other serotonergic medications in patients with refractory OCD have yielded inconsistent results. 25, 26 McDougle et al, 25 in their review article, found that enhancing serotonin neurotransmission to ongoing SSRI treatment in patients with refractory OCD has not yielded encouraging results. In contrast, in another review article, the addition of serotonin neurotransmission enhancers to patients with SSRI-refractory OCD has led to positive outcomes. 26 Furthermore, Denys et al, 23 in their study, found that 42% of the nonresponders to an SRI benefited from crossover to the other SRI, and that paroxetine was more efficacious than venlafaxine in the treatment of nonresponders to a previous SRI trial. Our study demonstrated that augmenting an SSRI with another SSRI in patients with resistant OCD would decrease the OCD symptoms and yield positive results. It also increased the patients' global clinical improvement.
Of note, enhancing serotonergic transmission with other serotonergic agents may increase intolerability to SSRI medications and result in more dropouts. Throughout our study, the patients were under close monitoring, and adverse effects were reported to researchers by the patients anytime an effect emerged. However, we had only 5 dropouts, which is not more than the dropouts observed in other augmenting factor trials in patients with OCD. 19 This may be due to slowly increasing the dose of sertraline and stopping escalation of the dose upon the patient's intolerability.
Another important issue that we were concerned about was the risk of serotonin syndrome. 27 The patients were educated about the signs and symptoms of serotonin syndrome, and they were asked to call the researcher immediately anytime they encounter any of those signs and symptoms. We did not observe any case of serotonin syndrome during the survey.
A small number of the patients and the short duration of the trial are the limitations of our survey. Another pitfall of our study was the lack of a placebo group. If duloxetine was compared with placebo, a better conclusion regarding its effects on OCD might be inferred. Larger double-blind, placebo-controlled clinical trials with more patients and with longer duration are needed to confirm our results.
CONCLUSIONS
Our double-blind, controlled clinical trial showed that duloxetine was as effective as sertraline in reducing obsessions and compulsions in patients with resistant OCD. However, it needs to be noted that our study is preliminary, and larger double-blind studies are necessary to confirm the results.
AUTHOR DISCLOSURE INFORMATION
This study was the graduation thesis of Dr Boostani for the School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
The authors declare no conflicts of interest.
